![]() An experienced management team established the company in 2009 following the successful trade sale of the B In addition, AiCuris receives royalties on world-wide sales.īut you do not always have to choose between private investors or venture capitalists, as the case of Adrenomed illustrates. To date, AiCuris has received upfront and milestone payments of EUR 260 million, from this agreement. In November 2017, Letermovir, now under the tradename PREVYMIS™, received FDA approval for the prevention of Cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients, followed by EU approval in January 2018. In 2012, the company licensed its proprietary lead candidate Letermovir (PREVYMIS™), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, to MSD, following a successful proof of concept Phase IIb study. Since then, their investment company SANTO Holding has remained AiCuris’ majority investor. ![]() Andreas and Thomas Strüngmann, who invested EUR 120 million in an initial financing round. The German company was founded in 2006 as a spin-off from Bayer with the financial support of Drs. APEIRON is also eligible to receive milestone payments and royalties in the collaborative research and product license option deals.Īnother example of successful private financing that resulted in a marketed drug is AiCuris Anti-infective Cures. As an important pillar in these ongoing collaborations the partners fund research and development activities for APEIRON. Additionally, APEIRON has completed pharma deals with GSK (2011) as well as Sanofi and Evotec (2015). ![]() In 2016 APEIRON successfully out-licensed the global commercialization and development rights of Qarziba (APN311) to EUSA Pharma and receives milestone payments and royalties. Furthermore, APEIRON’s board holds a significant interest in the company. Investors in the company include Austrian trusts and private investors as well as international pharmaceutical companies. The shareholder base of APEIRON Biologics, a Vienna-based biotech company with an approved product and operational since 2005, is a strong example of the HNWI and family office approach. However, there are signs that the importance and quality of private financings in private life science may be highly underestimated: Large single investments by family offices and private investment groups of HNWIs have recently celebrated important successes, market approvals, partnership and licensing deals or trade sales. Some venture capital investors are still arguing that family offices and HNWIs have underperformed the professional VC approach, in turn legitimizing the VC quasi monopoly. These discussions are due for a renewed airing at the upcoming BIO-Europe Spring ® 2019 conference in Vienna, Austria. On one side, the professional VC investors discussed strategies based on portfolios, IPOs and acquisitions, plus limited partners (LPs), while HNWIs and family offices had longer term visions and no LPs pressing for major returns.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |